Inovio Stock Up On Earnings, Pipeline Progress

Core Insights - Inovio Pharmaceuticals Inc reported a smaller fourth-quarter loss than expected, with a diluted loss of 26 cents per share, better than the analyst consensus of 38 cents and an improvement from a 65-cent loss a year earlier [2] - The company highlighted progress on its lead DNA medicine candidate, INO-3107, which has received FDA acceptance for its biologics license application, with a target action date of October 30 [3] Financial Performance - For the full year 2025, Inovio posted a net loss of $84.9 million, down from $107.3 million in 2024, while total operating expenses decreased to $86.9 million from $112.6 million [2] - The fourth-quarter results included a $21.2 million non-cash gain related to warrant liabilities, which can create volatility in reported income [3] Cash Position and Runway - The company ended 2025 with $58.5 million in cash, cash equivalents, and short-term investments, with resources expected to fund operations into the fourth quarter of 2026, including an estimated operational net cash burn of about $22 million in the first quarter of 2026 [4] Pipeline Developments - Inovio is advancing commercialization plans for INO-3107 and has announced a trial collaboration with Akeso to study INO-5412 in glioblastoma, providing additional pipeline catalysts for investors [4] Stock Performance - Inovio Pharmaceuticals shares were up 2.38% at $1.72 at the time of publication, indicating positive momentum in the stock [6]